Radiotherapy: PSA nadir predicts long-term mortality

Nature Reviews Clinical Oncology

Volumn 7, Issue 4, 2010, Pages 188-190

  Buyyounouski, Mark K ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

DISTANT METASTASIS; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; SHORT SURVEY;

DISEASE PROGRESSION; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77950496795     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.33     Document Type: Short Survey

References (10)

1. Zelefsky, M. J. et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int. J. Radiat. Oncol. Biol. Phys. 75, 1350-1356 (2009).
2. The nCCn Clinical Practice Guidelines in Oncology™ Prostate Cancer (Version 1.2010) [online]. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#site (2010).
3. Buyyounouski, M. K., Hanlon, A. L., Horwitz, e. M., Uzzo, R. G. & Pollack, A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 61, 1291-1298 (2005). (Pubitemid 40470409)
4. Zietman, A. L. et al. Use of PsA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother. Oncol. 40, 159-162 (1996).
5. Lee, w. R., Hanlon, A. L. & Hanks, G. e. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J. Urol. 156, 450-453 (1996). (Pubitemid 126445360)
6. Cavanaugh, s. X. et al. Time and PsA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer Prostatic Dis. 8, 353-358 (2005).
7. Ray, M. e. et al. nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 68, 1257-1262 (2006).
8. Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, e. M. & Pollack, A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109, 41-47 (2007). (Pubitemid 46120193)
9. Buyyounouski, M. K., Hanlon, A. L., Horwitz, e. M. & Pollack, A. interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70, 59-66 (2008). (Pubitemid 350251025)
10. Buyyounouski, M. K., Pickles, T., Kestin, L., Allison, R. & williams, s. G. validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75, s103-s104 (2009).